Event-Driven Stocks

PROKIDNEY CORP.

PROKNasdaq

Healthcare · Biological Products, (No Diagnostic Substances) · E9 · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs2 good4 warning2 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21
Revenue$893,000$76,000$0$0
Operating income−$165.0M−$183.7M−$151.5M−$153.0M−$2.3M
Net income−$69.0M−$61.2M−$35.5M−$54.5M−$2.3M
Total assets$335.6M$441.1M$420.6M$518.0M$251.2M
Total liabilities$34.8M$39.4M$29.2M$13.1M$9.6M
Equity−$1.01B−$995.0M−$1.10B−$1.10B$0
EPS (diluted)$-0.23
Shares out.61.5M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−18477.8%
Net margin
−7725.2%
Return on equity
6.8%
Return on assets
−20.6%
Return on capital (ROCE)
−54.1%
Liabilities / assets
10.4%
Debt / equity
Book value / share
Revenue growth (YoY)
1075.0%
Net income growth (YoY)

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-41.28distress
Accruals / assets
15.2%high accruals
Piotroski F-Score
2/8weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
41
/ 100
Profitability 20Growth 100Catalyst 33Earnings quality 0Financial strength 50

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

2 severe4 warning2 good
  • Negative shareholder equity
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Negative operating cash flow
  • High accruals — earnings-quality risk
  • Revenue is growing year-over-year
  • Conservative leverage (liabilities < 50% of assets)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202619.2M25.2+5.4%
Apr 30, 202618.3M27.5+3.8%
Apr 15, 202617.6M12.8+5.5%
Mar 31, 202616.7M18.2+8.8%
Mar 13, 202615.3M25.2-1.5%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (4)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.